Stock data
Supernus Pharmaceuticals, Inc. (SUPN)
Supernus Pharmaceuticals, Inc. (SUPN) reported revenue of US$718.95M and net income of -US$38.55M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$718.95M | — | -US$62.28M | -US$38.55M | — |
| 2024 | US$661.82M | — | US$81.67M | US$73.86M | — |
| 2023 | US$607.52M | — | -US$5.27M | US$1.32M | — |
| 2022 | US$667.24M | — | US$46.12M | US$60.71M | — |
| 2021 | US$579.77M | — | US$86.03M | US$53.42M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$219.06M | -US$58.37M | — |
| 2026-03-31 | US$207.71M | -US$2.29M | — |
| 2025-12-31 | US$211.57M | -US$4.11M | — |
| 2025-09-30 | US$192.10M | -US$45.12M | — |
| 2025-06-30 | US$165.45M | US$22.50M | — |
| 2025-03-31 | US$149.82M | -US$11.83M | — |
| 2024-12-31 | US$174.16M | US$15.33M | — |
| 2024-09-30 | US$175.69M | US$38.50M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.